Prospective Clinical Correlation of the Histoculture Drug Response Assay for Ovarian Cancer
The histoculture drug response assay (HDRA) has been correlated clinically to a number of cancer types (please see Chaps. 7– 11 of the present volume). The present chapter reviews the clinical trials of the HDRA for ovarian cancer. A prospective clinical trial of the HDRA for advanced epithelial ovarian cancer (AEOC) was performed at Asan Medical Center, Seoul, Korea. The clinical trial compared the efficacy of first-line therapy paclitaxel and carboplatinum in the HDRA and the clinical response for the patients whose tumors were tested in the HDRA. A series of patients (104) were treated with adjuvant combination chemotherapy of paclitaxel and carboplatinum after primary cytoreductive surgery. Tumor fragments were cultured on Gelfoam® and tested with paclitaxel and carboplatinum and evaluated with the MTT endpoint. Patients were categorized into two groups as either sensitive to both drugs (SS) or not sensitive to one or both drugs (R) based on HDRA results. The recurrence rate was much lower in the SS group compared to the R group, 29.2% vs. 69.8%, respectively. The SS group had a significantly longer progression-free survival compared to the R group, 34.0 months vs. 16.0 months, respectively. In another clinical trial, the HDRA was performed on 85 cases of ovarian cancer and 97% were evaluable. HDRA results were correlated to clinical response of 15 patients who received cisplatinum-based therapy that included doxorubicin and cyclophosphamide (CAP therapy). The true-positive rate was 88%, the true-negative rate was 86%, the sensitivity was 88%, the specificity was 86%, and the accurate prediction rate was 87% when HDRA results were compared to the response of the treated patients.
Key wordsGelfoam® histoculture HDRA Ovarian cancer Paclitaxel Carboplatinum Cisplatinum Recurrence Progression Survival Correlation Prospective Clinical trial
- 6.Furukawa T, Kubota T, Watanabe M, Takahara T, Yamaguchi H, Takeuchi T, Kase S, Kodaira S, Ishibiki K, Kitajima M et al (1992) High in vitro-in vivo correlation of drug response using sponge-gel-supported three-dimensional histoculture and the MTT end point. Int J Cancer 51:489–498CrossRefPubMedGoogle Scholar
- 12.Hoffman RM (2010) Histocultures and their use. In: Encyclopedia of Life Sciences. John Wiley and Sons, Ltd, Chichester. https://doi.org/10.1002/9780470015902.a0002573.pub2 Google Scholar
- 14.Kim JC, Kim DD, Lee YM, Kim TW, Cho DH, Kim MB, Ro SG, Kim SY, Kim YS, Lee JS (2009) Evaluation of novel histone deacetylase inhibitors as therapeutic agents for colorectal adenocarcinomas compared to established regimens with the histoculture drug response assay. Int J Color Dis 24:209–218CrossRefGoogle Scholar
- 21.Ohie S, Udagawa Y, Kozu A, Komuro Y, Aoki D, Nozawa S, Moossa AR, Hoffman RM (2000) Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide. Anticancer Res 20:2049–2054PubMedGoogle Scholar
- 22.Jung PS, Kim DY, Kim MB, Lee SW, Kim JH, Kim YM, Kim YT, Hoffman RM, Nam JH (2013) Progression-free survival is accurately predicted in patients treated with chemotherapy for epithelial ovarian cancer by the histoculture drug response assay in a prospective correlative clinical trial at a single institution. Anticancer Res 33:1029–1034PubMedGoogle Scholar